Background: Cochlear is the ASX-listed company behind the bionic ear and one of the world's biggest hearing implant makers. For years, it has been a major Australian healthcare success story, with investors accustomed to steady growth from a business operating in a highly specialised market.

But five months ago, Cochlear slashed its profit guidance from as high as $460 million to as low as $290 million, citing softer sales and uncertainty in the Middle East.  

What happened: Investors reacted immediately - the share price plunged 40% in a single day, wiping around $4 billion from its market value and taking the stock to its lowest level in more than decade. Now, shareholders have launched a class action in the Supreme Court of Victoria, covering investors who bought Cochlear shares during the eight months before the profit downgrade.

What else: Cochlear denies the allegations and says it will defend the case, arguing that its disclosures were appropriate. But when a company dramatically cuts its outlook and billions disappear from its market value, the question becomes whether investors were given enough information to understand the risks before the downgrade.

What's the key learning?

💡 On the ASX, companies are allowed to have a bad year... they just can't sit on news for very long. Listed companies have a continuous disclosure obligation, meaning if they know something that would move the share price, they generally have to tell the market pretty quickly.

💡 A bad profit update can become a class action when investors argue the company knew things were going south earlier than it let on. The argument is that shareholders bought shares at a price that, in hindsight, was too high because the market didn't have information that could have affected the share price.

💡 These cases are getting more serious. In April, Brambles, the ASX-listed logistics provider, became the first shareholder class action in Australia to win at trial after a court found it had failed to disclose a known change in its profit guidance. For Cochlear, the case will ultimately come down to what it knew, and when.